51. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
- Author
-
Xinghong Dai, Gavin R. Screaton, Wiyada Wongwiwat, Thaneeya Duangchinda, Jeremy Farrar, Z. Hong Zhou, Xiaokang Zhang, Carolyn Edwards, Cameron P. Simmons, Jonathan M. Grimes, Sunpetchuda Supasa, Chih Yun Lai, Wei-Kung Wang, Nguyen Than Ha Quyen, Wanwisa Dejnirattisai, Félix A. Rey, Prida Malasit, Juthathip Mongkolsapaya, Wen-Yang Tsai, Alexander Rouvinsky, Amonrat Jumnainsong, Wellcome Trust, Commission of the European Communities, and Medical Research Council (MRC)
- Subjects
TICK-BORNE ENCEPHALITIS ,Dengue virus ,medicine.disease_cause ,Epitope ,Neutralization ,Dengue fever ,Dengue ,Viral Envelope Proteins ,Monoclonal ,Immunology and Allergy ,IMMUNE-RESPONSE ,Neutralizing ,Antibodies, Monoclonal ,ENVELOPE GLYCOPROTEIN ,FUSION-LOOP ,Infectious Diseases ,1107 Immunology ,Biological Assay ,Antibody ,Infection ,Life Sciences & Biomedicine ,Biotechnology ,medicine.drug_class ,Immunology ,Immunoblotting ,Enzyme-Linked Immunosorbent Assay ,Biology ,MEMBRANE-FUSION ,Monoclonal antibody ,Virus ,Antibodies ,Article ,MATURATION ,Cell Line ,Vaccine Related ,Rare Diseases ,Immunity ,Biodefense ,medicine ,Animals ,Humans ,Science & Technology ,Prevention ,HUMAN MONOCLONAL-ANTIBODIES ,Dengue Virus ,medicine.disease ,Virology ,Antibodies, Neutralizing ,Vector-Borne Diseases ,Emerging Infectious Diseases ,Good Health and Well Being ,HEMORRHAGIC-FEVER ,biology.protein ,T-CELLS ,Immunization ,STRUCTURAL-CHANGES - Abstract
Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
- Published
- 2014